Inactive Instrument

Highlights Kane Biotech Inc Toronto S.E.

Equities

KNE

CA4838092084

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	Apr. 15	MT
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	Apr. 14	CI
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	Apr. 11	MT
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	Mar. 26	MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	Mar. 20	MT
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	Jan. 31	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	Nov. 28	MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022	Nov. 28	MT
Kane Biotech Brief: Total revenue for three months ended September 30, 2023 was $717,852, an increase of 26% compared to $571,686 in three months ended September 30, 2022	Nov. 28	MT
Kane Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum	Nov. 02	CI
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum	23-10-25	MT
Kane Biotech Inc. to Exhibit At Symposium on Advanced Wound Care Fall Forum	23-10-25	CI
Kane Biotech Second-Quarter Loss Widens Even as Revenue Rises 68%	23-08-29	MT
Kane Biotech Brief: Total revenue for the three months ended June 30, 2023 was $657,310, a decrease of 22% compared to $839,579 in the three months ended June 30, 2022	23-08-29	MT
Kane Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kane Biotech Inc Toronto S.E.

Equities

KNE

CA4838092084

Highlights

Filters